NyarkoK.A.Regulatory approach for subsequent entry biologics in Canada. Health Canada. Presented at the PMDA 3rd International Symposium on Biologics, Feb. 17, 2009, Tokyo, Japan. Texte publié sur le site www.pmda.go.jp/2009bio-sympo/file/IV-2_Nyarko_(Health%20Canada).pdf (consulté le 4 août 2009).
6.
ShacterE.Quantification and significance of protein oxidation in biological samples. Drug Metab Rev2000;32(3–4):307–26.
SharmaB.Immunogenicty of therapeutic proteins. Part 3: Impact of manufacturing changes. Biotechnol Adv2007;25:325–31.
9.
RossCClemmesenKSvensonMImmunogenicity of interferon-beta in multiple sclerosis patients: influence of preparations, dosage, dose frequency and route of administration. Ann Neurol2000;48:706–12.
10.
SchellekensH.Biosimilar therapeutics — what do we need to consider?NDT Plus2009;2[Suppl 1]:i27–i36.
SchellekensH.Biosimilar epoetins: how similar are they?Eur J Hosp Pharm Sci2004;3:43–7.
13.
McMahonERegulyT.Canada: biosimilars in Canada: new draft guidelines from Health Canada. Texte publié sur le site www.mondaq.com/article.asp?articleid=83460 (consulté le 4 août 2009).
14.
Organisation mondiale de la santé. WHO informal consultation on international nonproprietary names (INN) policy for biosimilar products. Geneva: World Health Organization; 2006. Texte publié sur le site www.who.int/medicines/services/inn/inn_bio/en/index.html (consulté le 3 juin 2009).